Hypertension
Conditions
Interventions
cilnidipine
amlodipine
Sponsors
Osaka university graduate school of medicine The department of geriatric medicine and nephrology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Age 65 and over 2.Stable hypertensive patients who receive amlodipine (<140/90 at outpatient clinic or <135/85 at home) or hypertensive patients who do not receive amlodipine. 3.Patients give written informed consent after sufficient explanation 4.Patients who have received the same anti-hypertensive medication during 6months.
Exclusion criteria
Exclusion criteria: 1.Secondary hypertension, malignant hypertension 2.Stroke or myocardial infarction during 6months 3.Coronary intervention during 6months 4.Congestive heart failure with NYHA class III or more 5.Aortic stenosis 6.Arterial fibrillation, arterial flutter or malignant arrhythmia 7.Severe hepatic injury 8.Sensitivity to trial drug 9.Excluded by physicians decision
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| (Comparison among step1, step2, and step3) Home BP variability (interdaily variability, intradaily variability (morning, night) BP variability during sleep Home pulse rate variability (interdaily variability, intradaily variability (morning, night) pulse rate variability during sleep | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.BP and pulse rate at outpatient (average of two measurements) 2.Index of oxidative stress 3.Renal function (Ualb/Cr. eGFR) 4.Sympathetic nerve activity | — |
Countries
Japan
Contacts
Public ContactKoichi Yamamoto
Osaka university graduate school of medicine The department of geriatric medicine and nephrology
Outcome results
None listed